Figure 1: status of IO clinical trials initiated during 2008–2017.

GlobalData has reviewed the status of global clinical trials in the immuno-oncology (IO) space that were initiated between 2008 and 2017. Over the 10-year period, 41% of trials were recruiting; 12% were not recruiting; 6% were planned; and 12% were suspended, terminated, or withdrawn (S/T/W), as shown in Figure 1.

Overall, 28% of trials were completed. This is complementary to the considerable growth that Immuno-Oncology trials have featured in recent years.

Additionally, in the majority of cases, the percentage of completed trials suggests that people should be cautious of making inferences about the efficacy of many interventions across various indications and therapy areas, as the majority of trials are still ongoing.

Among those completed trials, 68% reported results. Primary endpoints were achieved in 82% of these trials, not achieved in 10% of trials, inconclusive in 4% of trials, and partially achieved in 4% of trials.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.